DelveInsight’s “Chronic Obstructive Pulmonary Disease (COPD) Market Insights, Epidemiology, and Market Forecast–2036” report delivers an in-depth understanding of COPD, historical and forecasted epidemiology, as well as the COPD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the COPD Market with DelveInsight’s In-Depth Report @ COPD Market Size
Key Takeaways from the COPD Market Report
The leading COPD companies include GSK, Regeneron Pharmaceuticals, Sanofi, AstraZeneca, Verona Pharma, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., Roche, and others.
Rising prevalence of COPD globally — driven by tobacco smoking, biomass fuel exposure, air pollution, aging populations, and early-life lung insults — is accelerating demand for advanced maintenance and biologic therapies offering durable and targeted treatment outcomes.
Breakthroughs in biologic therapies (IL-4, IL-5, IL-33, and TSLP inhibitors), dual PDE3/4 inhibitors, and triple combination inhalers are expanding therapeutic applications and improving clinical efficacy across patient subgroups.
The COPD market in the 7MM is expected to witness major change during the study period 2022–2036.
Key targets currently under development include IL-5, IL-33, IL-4Rα, TSLP, PDE3/PDE4, A1AR, and others.
The total COPD market size across the 7MM was estimated at nearly USD 12.2 billion in 2025 and is expected to grow significantly by 2036.
Five major COPD therapies — TRELEGY ELLIPTA, ANORO ELLIPTA, SYMBICORT, BREO ELLIPTA, and SPIRIVA RESPIMAT — have been selected for the second round of Medicare price negotiations under the Inflation Reduction Act (IRA), with high price cuts anticipated in 2027.
Stay ahead in the COPD Market with DelveInsight’s Strategic Report @ COPD Market Outlook
COPD Epidemiology Segmentation in the 7MM
Total Diagnosed Prevalent Cases of COPD in the 7MM
Market Size by Therapies
Market Size by Class
COPD Treatment Market
COPD Pipeline Analysis
NUCALA (mepolizumab): GSK Pharmaceuticals NUCALA is a fixed-dose biologic therapy approved for subcutaneous injection targeting IL-5, preventing it from interacting with its receptor on eosinophils, thereby reducing eosinophilic inflammation. It is available as prefilled syringes, autoinjectors, and powder for injection. In May 2025, the US FDA approved NUCALA for use in adults with COPD, based on data from the METREX and METREO Phase III trials, which demonstrated a statistically significant reduction in moderate and severe exacerbations in patients with elevated eosinophil counts on maximum inhaled therapies. A filing for NUCALA in Europe is planned for 2026.
DUPIXENT (dupilumab): Regeneron Pharmaceuticals/Sanofi DUPIXENT is a monoclonal antibody targeting the alpha chain of the IL-4 receptor, inhibiting IL-4 and IL-13 — key drivers of Type 2 (TH2) inflammation. It is the first biologic approved in Europe (July 2024) and the United States (September 2024) for adults with inadequately controlled COPD with an eosinophilic phenotype. Two pivotal Phase III studies demonstrated that DUPIXENT effectively reduced exacerbations by approximately 30–34%, enhanced lung function, and improved health-related quality of life. Dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients.
OHTUVAYRE (ensifentrine): Verona Pharma OHTUVAYRE is a first-in-class selective dual inhibitor of PDE3 and PDE4 enzymes, combining bronchodilator and nonsteroidal anti-inflammatory effects in a single inhaled molecule. It met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials, demonstrating statistically significant and clinically meaningful improvements in lung function. FDA approved in June 2024 for the maintenance treatment of COPD. In July 2025, Merck announced its acquisition of Verona Pharma, adding OHTUVAYRE to its portfolio.
Depemokimab: GSK Depemokimab is the first ultra-long-acting biologic to be evaluated in a Phase III trial, with a high binding affinity and potency for IL-5, enabling 6-month dosing intervals for patients. IL-5 is a key cytokine in Type 2 inflammation, and depemokimab aims to reduce eosinophilic activity and associated exacerbations in COPD patients.
Itepekimab (REGN3500): Regeneron Pharmaceuticals/Sanofi Itepekimab is a fully human monoclonal antibody that binds to and inhibits IL-33, an initiator and amplifier of broad inflammation in COPD. In May 2025, Sanofi announced that the AERIFY-1 Phase III study met its primary endpoint of a statistically significant reduction in moderate or severe acute exacerbations in former smokers with inadequately controlled COPD. Itepekimab was granted Fast Track Designation (FTD) by the US FDA in January 2023.
Tozorakimab: AstraZeneca Tozorakimab is a human therapeutic monoclonal antibody with a dual pharmacological profile, inhibiting IL-33 activities through the ST2 and RAGE/EGFR signalling pathways. It has received FTD from the US FDA. In March 2026, AstraZeneca announced positive Phase III results from the OBERON and TITANIA trials, demonstrating a significant reduction in moderate-to-severe COPD exacerbations, reinforcing IL-33 inhibition as a promising therapeutic strategy.
COPD Market Insights
The current treatment landscape includes bronchodilators, inhaled corticosteroids, combination therapies, phosphodiesterase inhibitors, biologic agents, oxygen therapy, pulmonary rehabilitation, smoking cessation support, and surgical interventions. Historically, COPD treatment has centered around bronchodilator-based regimens, with LAMAs and LABAs forming the treatment backbone. Double therapy (LAMA/LABA) is preferred for moderate symptoms, and triple therapy (LAMA/LABA/ICS) is reserved for severe COPD or patients with frequent exacerbations.
Since 2024, biologics and dual PDE3/4 inhibitors have been introduced, marking a pivotal shift in COPD management. Treatments such as OHTUVAYRE and biologics targeting Type 2 inflammation (NUCALA, DUPIXENT) are expanding therapeutic options for patients with frequent exacerbations or overlapping inflammatory phenotypes. As precision medicine advances and new drugs gain approval, the COPD market is likely to see increased segmentation and a shift toward more personalized, targeted treatment approaches.
The competitive landscape is highly dynamic and innovation-driven, with leading players advancing biologic therapies across IL-5, IL-33, IL-4Rα, and TSLP pathways alongside novel small molecules. Strategic collaborations, licensing agreements, and mergers are actively shaping the pipeline. Notably, five major branded COPD therapies face significant pricing pressure through the IRA’s Medicare price negotiations, with cuts anticipated in 2027.
The expected introduction of emerging therapies with improved efficacy, greater awareness initiatives, and continued improvement in diagnosis rates are likely to boost market growth across the 7MM.
Get In-Depth Knowledge on COPD Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
COPD Market Outlook
Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition marked by chronic respiratory symptoms — including dyspnea, coughing, mucus production, and recurrent exacerbations — resulting from structural abnormalities in the airways and/or alveoli, leading to persistent and often progressive airflow limitation. COPD is a leading cause of morbidity and mortality worldwide, inducing an economic and social burden that is both substantial and increasing.
The COPD treatment paradigm has evolved across four broad phases: the monotherapy era (ICS, LABA, LAMA), dual combination therapies (LABA/LAMA or LABA/ICS), triple combination therapy (LAMA/LABA/ICS), and now a transition toward biologic therapies focused on Type 2 inflammation. Women, rural populations, and those with low socioeconomic status face higher disease burden, lower diagnosis rates, and worse outcomes, highlighting the need for personalized, inclusive care.
The COPD pipeline is very robust, with many potential therapies under investigation across Phase I through Phase III. Market growth may be offset by therapy failures or discontinuations, pricing pressures under the IRA, market access and reimbursement barriers, and a scarcity of healthcare specialists.
Scope of the COPD Market Report
Coverage: 7MM
Study Period: 2022–2036
Forecast Period: 2026–2036
COPD Companies: GSK, Sanofi, Regeneron Pharmaceuticals, Verona Pharma, AstraZeneca, Chiesi Farmaceutici S.p.A., Boehringer Ingelheim, Roche, Merck, and others
COPD Therapies: NUCALA, DUPIXENT, OHTUVAYRE, BREZTRI AEROSPHERE, TRELEGY ELLIPTA, Depemokimab, Itepekimab, Tozorakimab, Tanimilast, Astegolimab, TEZSPIRE, FASENRA, and others
COPD Market Access & Reimbursements, Unmet Needs and Perspectives
COPD SWOT Analysis, Conjoint Analysis, and KOL Views
Unlock Strategic Insights with DelveInsight’s Comprehensive COPD Market Report @ COPD Market Drivers and Barriers
Table of Contents
Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
COPD Market Overview at a Glance
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Marketed Therapies
Emerging Drugs
COPD: 7MM Analysis
Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Related Reports
Chronic Obstructive Pulmonary Disease (COPD)- Market Insight, Epidemiology and Market Forecast -2030
DelveInsight’s ‘Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Chronic Obstructive Pulmonary Disease (COPD) – Epidemiology Forecast – 2034
DelveInsight’s ‘COPD– Epidemiology– 2034’ report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
